Farabi Pharmaceutical (XTEH:DFRB1) ROCE %: 0.00% (As of . 20)


What is Farabi Pharmaceutical ROCE %?

Farabi Pharmaceutical XTEH:DFRB1 ROCE % is 0.00% as of . 20.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Farabi Pharmaceutical's annualized ROCE % for the quarter that ended in . 20 was 0.00%.

Farabi Pharmaceutical  (XTEH:DFRB1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Farabi Pharmaceutical ROCE % Related Terms

Farabi Pharmaceutical ROCE % Historical Data

* Premium members only.

The historical data trend for Farabi Pharmaceutical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical ROCE % Chart

Farabi Pharmaceutical Annual Data
Trend
ROCE %

Farabi Pharmaceutical Quarterly Data
ROCE %

Farabi Pharmaceutical ROCE % Calculation

Farabi Pharmaceutical's annualized ROCE % for the fiscal year that ended in . 20 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( ( ( - ) + ( - ) )/ )
=/( (+)/ )
=/
= %

Farabi Pharmaceutical's ROCE % of for the quarter that ended in . 20 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( ( ( - ) + ( - ) )/ )
=/( ( + )/ )
=/
= %

(1) Note: The EBIT data used here is four times the quarterly (. 20) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a ROCE % of 0.00% as of . 20.
Is Farabi Pharmaceutical's ROCE % too high?
Farabi Pharmaceutical's current ROCE % is 0.00%.
How does Farabi Pharmaceutical's ROCE % compare to IMNPQ and INNV?
Farabi Pharmaceutical's ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farabi Pharmaceutical's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current ROCE % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.